Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Yu. Yu. Kiselev"'
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4S, Pp 35-38 (2020)
No published trials measuring effectiveness of tofacitinib in COVID-19 have been identified. Some professional associations recommend discontinuing tofacitinib if SARS-CoV-2 infections is detected. Taken into account possible complications of the use
Externí odkaz:
https://doaj.org/article/00165038867c4fbb8c2f8e51b4ffc965
Autor:
Yu. Yu. Kiselev, K. A. Zagorodnikova, D. V. Ivashchenko, A. V. Krykov, I. N. Sychev, A. S. Matveev, K. B. Mirzaev, V. A. Otdelenov, V. M. Tsvetov, A. V. Dmitriev, V. V. Poroikov, D. A. Sychev
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4S, Pp 75-80 (2020)
At the time of print, the evidence for using umifenovir in COVID-19 is mainly theoretical. The published clinical trials have contradicting results. The decision to use umifenovir in COVID-19 should be individualized, considering the “experimental
Externí odkaz:
https://doaj.org/article/086bc563d1bf4e7db1fc4d0bf2b37ae3
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4S, Pp 23-27 (2020)
No robust evidence proving clinical effectiveness of methylprednisolone in acute respiratory distress-syndrome in COVID-19, including combined use with tocilizumab, has been identified. Systemic glucocorticosteroids use may be considered acceptable i
Externí odkaz:
https://doaj.org/article/2b3e5d4f5bd64395a4ef5984255861cf
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4S, Pp 53-59 (2020)
Taking recent publications into account, one should consider avoiding routine use of hydroxychloroquine, especially if combined with azithromycin, for COVID-19. Such treatment may be associated with the increased risk for hospital mortality and QT pr
Externí odkaz:
https://doaj.org/article/277ef40b470e486eb66c951af4df2b9b
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4S, Pp 4-7 (2020)
There are no data on the clinical efficacy of the preparation containing sodium aminodihydrophthalazindione in «cytokine storm», including in patients with COVID-19. Protocols of planned or ongoing clinical trials of a preparation containing sodium
Externí odkaz:
https://doaj.org/article/56938ffe77824b8e8c06d36e9d965710
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4S, Pp 106-114 (2020)
There are experimental and clinical data regarding the activity of favipiravir against the SARS-CoV-2 virus. The is evidence of significant variability in pharmacokinetics and associated achievement of the required inhibitory concentration of the dru
Externí odkaz:
https://doaj.org/article/567cc0859414487dbb2db2e0cf5bb993
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4S, Pp 71-74 (2020)
There exist some theoretical premises for the use of colchicine in patients with COVID-19, and clinical trials are underway. There is currently no published evidence confirming effectiveness and safety of colchicine in COVID-19 and allowing to recomm
Externí odkaz:
https://doaj.org/article/8cf1e0fe32ad4fa08d95bd7162a8f36b
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4S, Pp 115-119 (2020)
Global experience with the clinical use of favipiravir is very limited. Its safety is for further study. Prevention of teratogenic effects (mandatory pregnancy test before starting therapy, compliance with effective contraception by both women and me
Externí odkaz:
https://doaj.org/article/d4cde7067a90469d8924571b9997b8c5
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4S, Pp 32-34 (2020)
Hyaluronidase is currently not included into Russian or foreign guidelines on the treatment of acute respiratory distress-syndrome in patients with COVID-19, and such treatment is not supported by evidence of clinical effectiveness. Hyaluronidase can
Externí odkaz:
https://doaj.org/article/ff66ec853b554dfe8d7d5918b8f5d217
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4S, Pp 47-49 (2020)
Some guidelines describe combined use of hydroxychloroquine and lopinavir/ritonavir as one of the treatment alternatives for severe COVID-19, yet this treatment is not preferable. It requires careful consideration of possible interactions with other
Externí odkaz:
https://doaj.org/article/89914ec010bb4e33b3be38adc7e46feb